CARBIDOPA AND LEVODOPA Carbidopa 25 MG Levodopa 100 MG Oral Tablet
INDICATIONS AND USAGE Carbidopa and levodopa tablets, USP are indicated in the treatment of Parkinson's disease, post-encephalitic parkinsonism, and symptomatic parkinsonism that may follow carbon monoxide intoxication or manganese intoxication. Carbidopa allows patients treated for Parkinson's disease to use much lower doses of levodopa. Some patients who responded poorly to levodopa have improved on carbidopa and levodopa tablets, USP. This is most likely due to decreased peripheral decarboxylation of levodopa caused by administration of carbidopa rather than by a primary effect of carbidopa on the nervous system. Carbidopa has not been shown to enhance the intrinsic efficacy of levodopa. Carbidopa may also reduce nausea and vomiting and permit more rapid titration of levodopa.
Sun Pharmaceutical Industries Limited
OVAL YELLOW 518
518 OVAL YELLOW
Related Pills
Carbidopa 10 MG Levodopa 100 MG Oral Tablet
Sun Pharmaceutical Industries Limited
CARBIDOPA AND LEVODOPA Carbidopa 25 MG Levodopa 100 MG Oral Tablet
Sun Pharmaceutical Industries Limited
DISCLAIMER:
"This tool does not provide medical advice, and is for informational and educational purposes only, and is not a substitute for professional medical advice, treatment or diagnosis. Call your doctor to receive medical advice. If you think you may have a medical emergency, please dial 911."
"Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service."
"This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product."
PillSync may earn a commission via links on our site
HOW SUPPLIED
CARBIDOPA AND LEVODOPA tablets, USP 25 mg/100 mg are mottled (orange colored speckles) yellow to light yellow colored oval shaped, biconvex, uncoated tablets debossed with "518" on one side and plain on the other side. They are supplied as follows: Bottle of 30 with child-resistant closure, NDC 62756-518-83 Bottle of 100 with child-resistant closure, NDC 62756-518-88 Bottle of 100, NDC 62756-518-08 Bottle of 500, NDC 62756-518-13 Bottle of 1000, NDC 62756-518-18
CARBIDOPA AND LEVODOPA tablets, USP 10 mg/100 mg are mottled blue to light blue colored oval shaped, biconvex, uncoated tablets debossed with "517" on one side and plain on the other side. They are supplied as follows: Bottle of 30 with child-resistant closure, NDC 62756-517-83 Bottle of 100 with child-resistant closure, NDC 62756-517-88 Bottle of 100, NDC 62756-517-08 Bottle of 500, NDC 62756-517-13 Bottle of 1000, NDC 62756-517-18
CARBIDOPA AND LEVODOPA tablets, USP 25 mg/250 mg are mottled blue to light blue colored oval shaped, biconvex, uncoated tablets debossed with "519" on one side and plain on the other side. They are supplied as follows: Bottle of 30 with child-resistant closure, NDC 62756-519-83 Bottle of 100 with child-resistant closure, NDC 62756-519-88 Bottle of 100, NDC 62756-519-08 Bottle of 500, NDC 62756-519-13 Bottle of 1000, NDC 62756-519-18
CARBIDOPA AND LEVODOPA tablets, USP 25 mg/250 mg are mottled blue to light blue colored round shaped, biconvex, uncoated tablets debossed with "519" on one side and plain on the other side. They are supplied as follows: Bottle of 100 with child-resistant closure, NDC 62756-985-01 Bottle of 500, NDC 62756-985-02 Storage Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Store in a tightly closed container, protected from light and moisture. Dispense in a tightly closed, light-resistant container.
More pills like OVAL 518